医学
血管运动性鼻炎
布地奈德
氮芥
可视模拟标度
麻醉
胃肠病学
内科学
药理学
哮喘
作者
Ruyu Tan,Yifan Meng,Yang Wang,Lili Zhang,Chengshuo Wang,Luo Zhang
出处
期刊:ORL
[S. Karger AG]
日期:2023-01-01
卷期号:85 (6): 321-328
摘要
<b><i>Introduction:</i></b> Relevant studies have demonstrated that glucocorticoids and antihistamines, such as budesonide and azelastine, are effective in the treatment of vasomotor rhinitis, with their combined use being more effective than that of a single drug. The aim of this study was to assess the improvement in the symptoms of patients following the combined administration of these drugs. <b><i>Methods:</i></b> We conducted a single-center randomized study on 42 patients. Participants were randomly treated with budesonide, levocabastine hydrochloride, or their combination for 2 weeks. The visual analog scale (VAS) score and levels of eosinophil cationic protein (ECP), histamine (HA), leukotriene B4 (LTB4), and vasoactive intestinal peptide (VIP) in nasal secretions were evaluated before and after treatment. <b><i>Results:</i></b> The symptoms of patients were improved in all 3 treatment groups compared with those before treatment. Following combined treatment, the improvement in symptoms of nasal obstruction, runny nose, nasal itching, and sneezing was much greater than those in the groups treated with budesonide or levocabastine hydrochloride alone (<i>p</i> = 0.04, 0.004, 0.005, 0.004, respectively). The decreased levels of these inflammatory mediators were significantly different between the different treatment groups. <b><i>Conclusions:</i></b> Budesonide or levocabastine hydrochloride alone improved the nasal symptoms of patients with vasomotor rhinitis and reduced the levels of ECP, HA, LTB4, and VIP in nasal secretions. However, their combination improved the symptoms of patients more significantly than each drug alone.
科研通智能强力驱动
Strongly Powered by AbleSci AI